Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DBV Technologies S.A. - American Depositary Shares (NQ:DBVT)

18.45 -0.09 (-0.51%)
Streaming Delayed Price Updated: 11:50 AM EDT, May 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about DBV Technologies S.A. - American Depositary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Combined General Meeting of June 3, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports First Quarter 2026 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in Upcoming March Investor Conferences
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Reports Third Quarter 2025 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Announces Resignation of Board Member
From DBV Technologies S.A.
Via GlobeNewswire
News headline image
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.